Takeda wants to transform the treatment of rare diseases into Immunology and Lysosomal Storage Disorders (DDL). These rare genetic and metabolic disorders can have very variable symptoms and progress very differently from person to person, which means that patients take a long time to be diagnosed, at least at the beginning of their diagnostic journey.